Ozempic vs Wegovy is a comparison of finished medicines that share semaglutide. In Canada, the ingredient name is only the beginning of the record check. The brand, formulation, indication, presentation and current product monograph determine what a particular authorization covers. A comparison should not turn that shared ingredient into instructions for switching products.
Same molecule does not mean the same product record
Health Canada’s peptide overview names Ozempic, Wegovy and Rybelsus as examples of semaglutide products. The Canadian Ozempic monograph identifies its own indications and formulation. Wegovy must be checked against its separate current entry in the Drug Product Database.
This is why a search for “semaglutide Canada” can mix information about diabetes care, weight management, oral delivery and different products. Keep the brand and the Canadian record in view before interpreting a page written for another market.
Compare the right fields
Scroll horizontally to read all columns.
| Field | Why it belongs in the comparison |
|---|---|
| Active ingredient | Confirms the shared semaglutide identity |
| Indication | States the populations and purposes in the current Canadian authorization |
| Dosage form and presentation | Identifies the actual finished product rather than a generic ingredient label |
| Clinical evidence | Shows which formulation, study population and outcome were evaluated |
| Safety information | Retains product-specific contraindications, warnings and adverse reactions |
Recording these fields is more useful than copying a conversion chart. A device presentation and its labelling are part of a medicine’s use; a website cannot establish interchangeability by comparing the chemical name alone.
Why trial averages need their original population
The STEP 1 trial studied semaglutide in adults with overweight or obesity without diabetes, with a defined intervention and accompanying lifestyle support. It does not describe every use of every semaglutide product. A diabetes trial may have a different baseline population, outcome priority and treatment context.
A fair reading therefore asks whether the headline concerns weight, glycaemic control, cardiovascular events or another endpoint. Even with the same molecule, those are different questions. Our semaglutide dossier and SELECT guide keep those settings separate.
Authorization, coverage and availability are different
A product can have an authorization record without being stocked at every pharmacy or covered by every benefit plan. A provincial or private insurer’s decision is not the same event as a federal regulatory decision. This article does not quote a universal Canadian price, promise coverage or infer local inventory from a database entry.
For a coverage comparison, retain the exact product and the plan’s own current criteria. For an authorization comparison, retain the DIN and monograph. Those records should not be collapsed into one “available in Canada” label.
Where generic and compounded products fit
Authorized generic semaglutide and compounded preparations introduce further distinctions. A generic product has its own regulatory record; a compounded preparation follows a different context. Read generic semaglutide in Canada and the compounding comparison before treating all semaglutide listings as equivalent. This is a guide to reading product evidence, not selecting treatment or a dose.
